Open AccessRenal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results
Author(s) -
M.R. Weir,
P.A. McCullough,
J.B. Buse,
J. Anderson
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/gj5n-9239
Subject(s) - canagliflozin , medicine , diabetes mellitus , type 2 diabetes , kidney disease , transporter , disease , endocrinology , empagliflozin , kidney , chemistry , biochemistry , gene